ArticlePharmaceutics2018
RETRACTED: Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin B.
Article in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- RETRACTED: Mehenni et al. Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin B.Pharmaceutics · 2026Article
- Development of Oral pH-Sensitive Eudragit L100-FunctionalizedACS omega · 2026Article
- Development and Formulation of Nanofiber-Based Ophthalmic Inserts for the Treatment of Fungal Keratitis.Pharmaceutics · 2026Article
- Comparative evaluation of ternary amorphous solid dispersions: Identifying optimal excipient systems for enhancing drug solubility.International journal of pharmaceutics: X · 2025Review
- Enhanced Skin Delivery of Amphotericin B: Development and Evaluation of Polymeric Nanoparticles Using a Porcine Ear Model.ACS omega · 2025Article
- Review
- Lipase-Responsive Amphotericin B Loaded PCL Nanoparticles for Antifungal Therapies.Nanomaterials (Basel, Switzerland) · 2022Article
- Design of double functionalized carbon nanotube for amphotericin B and genetic material delivery.Scientific reports · 2022Article
- Development of a Solid Dispersion of Nystatin with Maltodextrin as a Carrier Agent: Improvements in Antifungal Efficacy againstPharmaceuticals (Basel, Switzerland) · 2021Article
- Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing.Pharmaceutics · 2021Article
- Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil.Molecules (Basel, Switzerland) · 2021Article
- Affinity Effects on the Release of Non-Conventional Antifibrotics from Polymer Depots.Pharmaceutics · 2020Article
- Preparation, Characterization, and In Vivo Pharmacokinetic Study of the Supercritical Fluid-Processed Liposomal Amphotericin B.Pharmaceutics · 2019Article
- β-Cyclodextrin as a Functional Excipient Used for Enhancing the Diminazene Aceturate Bioavailability.Pharmaceutics · 2019Article
Corrections and comments
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, new polymer microspheres of amphotericin B (AmB) were prepared by a spray drying technique using cyclodextrin polymers (Poly-CD) to improve the solubility and dissolution of AmB, to prevent in vivo toxic AmB aggregations. Formulations were characterized through scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), thermal analysis, Raman spectroscopy, particle size, drug purity test and in vitro release studies. The analysis indicated that the chemical structure of AmB remained unchanged in the amorphous solid dispersion, but the structure was changed from crystalline to amorphous. AmB was completely release from such optimized formulations in dissolution media in 40 min. This work may contribute to a new generation of spherical amorphous solid dispersion using a cyclodextrin polymer, which has implications for the possibility of drug development for oral utilization or as powder aerosols for pulmonary administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.